3390 related articles for article (PubMed ID: 10837072)
21. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
Forde J; Volpe JM; Ciupe SM
Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
[TBL] [Abstract][Full Text] [Related]
22. Can antiretroviral therapy ever be stopped?
Siliciano R
AIDS Read; 2000 Apr; 10(4):224-9. PubMed ID: 10808605
[TBL] [Abstract][Full Text] [Related]
23. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
[TBL] [Abstract][Full Text] [Related]
24. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.
Rong L; Perelson AS
PLoS Comput Biol; 2009 Oct; 5(10):e1000533. PubMed ID: 19834532
[TBL] [Abstract][Full Text] [Related]
25. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.
Siliciano JD; Siliciano RF
Methods Mol Biol; 2005; 304():3-15. PubMed ID: 16061962
[TBL] [Abstract][Full Text] [Related]
26. Establishment of latent HIV-1 infection of resting CD4(+) T lymphocytes does not require inactivation of Vpr.
Shen A; Siliciano JD; Pierson TC; Buck CB; Siliciano RF
Virology; 2000 Dec; 278(1):227-33. PubMed ID: 11112497
[TBL] [Abstract][Full Text] [Related]
27. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
28. Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients.
Petitjean G; Al Tabaa Y; Tuaillon E; Mettling C; Baillat V; Reynes J; Segondy M; Vendrell JP
Retrovirology; 2007 Aug; 4():60. PubMed ID: 17727722
[TBL] [Abstract][Full Text] [Related]
29. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
30. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.
Chun TW; Justement JS; Lempicki RA; Yang J; Dennis G; Hallahan CW; Sanford C; Pandya P; Liu S; McLaughlin M; Ehler LA; Moir S; Fauci AS
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1908-13. PubMed ID: 12552096
[TBL] [Abstract][Full Text] [Related]
31. Measuring the Frequency of Latent HIV-1 in Resting CD4⁺ T Cells Using a Limiting Dilution Coculture Assay.
Laird GM; Rosenbloom DI; Lai J; Siliciano RF; Siliciano JD
Methods Mol Biol; 2016; 1354():239-53. PubMed ID: 26714716
[TBL] [Abstract][Full Text] [Related]
32. Hide-and-seek: the challenge of viral persistence in HIV-1 infection.
Geeraert L; Kraus G; Pomerantz RJ
Annu Rev Med; 2008; 59():487-501. PubMed ID: 17845138
[TBL] [Abstract][Full Text] [Related]
33. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
Moriuchi H; Moriuchi M
Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
[TBL] [Abstract][Full Text] [Related]
34. Gradual shutdown of virus production resulting in latency is the norm during the chronic phase of human immunodeficiency virus replication and differential rates and mechanisms of shutdown are determined by viral sequences.
Li XD; Moore B; Cloyd MW
Virology; 1996 Nov; 225(1):196-212. PubMed ID: 8918547
[TBL] [Abstract][Full Text] [Related]
35. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
36. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.
Re MC; Vitone F; Bon I; Schiavone P; Gibellini D
New Microbiol; 2006 Apr; 29(2):81-8. PubMed ID: 16841548
[TBL] [Abstract][Full Text] [Related]
37. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Chun TW; Engel D; Berrey MM; Shea T; Corey L; Fauci AS
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8869-73. PubMed ID: 9671771
[TBL] [Abstract][Full Text] [Related]
38. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
Kulkosky J; Pomerantz RJ
Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
[TBL] [Abstract][Full Text] [Related]
39. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips.
Rong L; Perelson AS
Math Biosci; 2009 Jan; 217(1):77-87. PubMed ID: 18977369
[TBL] [Abstract][Full Text] [Related]
40. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
